RTI-HS Home
› Our Services
› Market Access
› Asset Valuation
Asset Valuation
We can help you develop valuation models that are tailored specifically to your assets and market potential. The Valuation models estimate net present value (NPV) using discounted cash flows and / or real options calculations based on relevant parameters including development costs, sales and marketing costs, manufacturing costs, distribution costs, market size, market share, and drug price. The models use estimates of the probability of success in the remaining stages of drug development (Phase 2, Phase 3, and regulatory approval) using known clinical trial statistics in appropriate indications or therapeutic areas. We populate the models using available data; however, the models are constructed so that users can easily modify parameters in order to test various scenarios.
When you collaborate with us to develop valuation models or any other Decision-Analytic models you can be confident in their predictive ability, and application to your product development and commercialization decisions.
We also have experience in reimbursement due diligence to inform asset valuations. Due diligence can be a stand alone project or part of a comprehensive project that includes an asset valuation model.
We evaluate the reimbursement environment for existing and emerging products from several perspectives:
- Reimbursement and pricing research,
- Qualitative market research with payers, physicians, and other health stakeholders
- Health policy research
Additionally, we:
- Evaluate alternative technologies to characterize reimbursement and pricing opportunities and risks
- Compare the reimbursement potential of products in your portfolio
- Assess products to help you develop in-licensing, out-licensing and exit strategies
Related Services
For your projects that may have cross-functional requirements, we also offer the following complementary services:
